Damon Runyon Researchers

Meet Our Scientists
Shaogeng (Steven) Tang, PhD

Dr. Tang is interested in discovering small-molecule inhibitor drugs that target human immune-checkpoint proteins, including programmed cell death protein 1 (PD-1), using a combination of biochemistry, protein engineering, structural biology and immunology approaches. These small-molecule inhibitors would offer safety advantages resulting from their much shorter half-lives as compared to FDA-approved monoclonal antibody therapies, and possibly also offer efficacy advantages resulting from increased penetration and distribution within the tumor microenvironment. His work has broad implications for the development of a novel methodology for small-molecule drug discovery and the design of new cancer immunotherapies. 

Project title: "Toward small-molecule inhibitors against human immune checkpoint PD-1"
Institution: Stanford University
Named Award: Merck Fellow
Award Program: Fellow
Sponsor(s) / Mentor(s): Peter S. Kim, PhD
Cancer Type: All Cancers
Research Area: Biochemistry